Premium
Utility of serum ECPKA autoantibody assessment for various cancer diagnostic marker
Author(s) -
Kim KiNam,
Lee Seung Ho,
Sohn SungHwa,
Kim YuRi,
Seo SangHee,
Kim HyeWon,
Lee Seung Min,
Shim BooIm,
Kim In Kyoung,
Choi Chul Won,
Kim JunSuk,
Kim MeyoungKon
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.lb77-b
Subject(s) - autoantibody , immunoassay , cancer , medicine , antibody , immunology , metastasis , cancer biomarkers , cancer research
Background: Serum ECPKA is an extracellular form of Protein Kinase A, which is over‐expressed but also to be secreted outside the cell in various cancer patients. Purpose: We examined the concentration of an ECPKA in cancer patients compared to non‐cancer subjects and developed a highly sensitive enzyme immunoassay (EIA) for measuring IgG autoantibody against ECPKA as a cancer diagnostic marker. Material and Methods: 210 cancer patient and 129 normal subjects were included. Basic methodology for ECPKA assay was established an enzyme‐linked immunosorbent assay (ELISA) to measure the presence of anti‐ECPKA autoantibody in the human sera. Results: Compared with normal subjects, we found that the frequency of anti‐ECPKA IgG autoantibody was significantly higher in cancer patients (88%) than in those without cancer (17%). Furthermore the presence of anti‐ECPKA autoantibody in the serum of cancer patients was highly correlated with the site of metastasis. Conclusion: The immunoassay developed for anti‐ECPKA antibody is highly sensitive and specific. Therefore, early detection of an autoantibody‐based cancer may have clinical application and may become an important advance over current technology.